CRISPR-Cas9-based target validation for p53-reactivating model compounds

Inactivation of the p53 tumor suppressor by Mdm2 is one of the most frequent events in cancer, so compounds targeting the p53-Mdm2 interaction are promising for cancer therapy. Mechanisms conferring resistance to p53-reactivating compounds are largely unknown. Here we show using CRISPR-Cas9–based ta...

全面介紹

Na minha lista:
書目詳細資料
發表在:Nat Chem Biol
Main Authors: Wanzel, Michael, Vischedyk, Jonas B, Gittler, Miriam P, Gremke, Niklas, Seiz, Julia R, Hefter, Mirjam, Noack, Magdalena, Savai, Rajkumar, Mernberger, Marco, Charles, Joël P, Schneikert, Jean, Bretz, Anne Catherine, Nist, Andrea, Stiewe, Thorsten
格式: Artigo
語言:Inglês
出版: 2015
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4910870/
https://ncbi.nlm.nih.gov/pubmed/26595461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nchembio.1965
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍